Potential clinical utility of liquid biopsies in ovarian cancer

Zhu, Jie Wei; Charkhchi, Parsa; Akbari, Mohammad R.

doi:10.1186/s12943-022-01588-8

Table 3 Clinical utility of ctDNA as liquid biopsy for predicting and monitoring response to treatment

From: Potential clinical utility of liquid biopsies in ovarian cancer

Author, Year	Tumour Classification	Sample Size	Laboratory Methodology	Detected Abnormality	Treatment Protocol	Clinical Application	Ref
Gifford et. al, 2004	Stage Ic-IV EOC	138	Microsatellite PCR	hMLH1 methylation	Paclitaxel/docetaxel + carboplatin	Response monitoring	[215]
Swisher et al., 2005	Stage I-IV EOC	137	DNA sequencing	p53 mutation	Taxane + platinum agent	Response monitoring	[58]
Capizzi et al., 2008	Stage III-IV EOC	22	RT-PCR	Serum level	Carboplatin + paclitaxel or carboplatin only	Response monitoring	[216]
Kamat et al., 2010	Stage I-IV EOC	164	RT-PCR	Beta-globin	Platinum agent	Response monitoring	[217]
Wimberger et al., 2011	Stage Ib-IV EOC	62	Fluorescence	Fluorimetry	Carboplatin + paclitaxel	Response monitoring	[218]
Forshew et al., 2012	HGSOC	38	TAm-Seq, dPCR	TP53, PTEN, BRAF, KRAS, EGFR, PIK3CA mutations	Carboplatin + paclitaxel or epirubicin + cisplatin + capecitabine	Response monitoring	[162]
Murtaza et al., 2013	Stage III-IV	3	NGS, qPCR	RB1, ZEB2, BUB1, CES4A, MTOR, PARP8 mutations	Cisplatin, paclitaxel or carboplatin + paclitaxel	Response monitoring	[168]
Choudhuri et al., 2014	Stage IIIb/c	100	RT-PCR	Serum level	Carboplatin + paclitaxel	Response monitoring	[219]
Martignetti et al., 2014	Stage IIIc Serous Papillary	1	RT-PCR	FGFR2 fusion transcript	Carboplatin + paclitaxel (total 5 lines of treatment)	Response monitoring	[220]
Pereira et al., 2015	Stage I-IV Serous	22	WES, ddPCR, TGS	TP53, PTEN, PIK3CA, MET, KRAS, FBXW7, BRAF mutations	Platinum + taxane agent	Response monitoring	[163]
Piskorz et al., 2016	HGSOC	18	NGS	TP53 mutation	Platinum agent	Response monitoring	[91]
Parkinson et al., 2016	Relapsed HGSOC	40	Digital PCR	TP53 mutation	Heterogeneous standard of care treatment	Response monitoring	[164]
Flanagan et al., 2017	Relapsed Stage I-IV Serous	247	NGS	Methylation at CpG sites	Platinum agent	Response monitoring	[221]
Widschwendter et al., 2017	Stage I-IV HGSOC or Clear Cell	151	TUC-BS & RRBS	COL23A1, C2CD4D and WNT6 candidate markers	Carboplatin + paclitaxel or carboplatin only	Response monitoring	[161]
Ratajska et al., 2017	Stage I-IV	121	NGS	BRCA1/2 mutations	PARPi	Predict eligibility for PARPi	[222]
Christie et al., 2017	Stage I-IV HGSOC	30	NGS	BRCA reversion mutation	Platinum-based agent and/or PARPi	Predict treatment response	[213]
Weigelt et al., 2017	Stage III-IV	19	NGS	BRCA reversion mutation	Platinum-based agent ± taxane agent	Response monitoring	[214]
Giannopoulou et al., 2018	Stage I-IV HGSOC	50	RT-MSP	ESR1	Carboplatin + paclitaxel	Response monitoring	[153]
Du et al., 2018	Recurrent Stage II-III Serous	21	NGS	TP53, BRCA1, NOTCH2, DNMT3A mutations and CNVs	Platinum-based agent	Response monitoring	[165]
Morikawa et al., 2018	Stage I-IV Clear Cell	29	ddPCR	KRAS, PIK3CA	Carboplatin + paclitaxel ± docetaxel/carboplatin/gemcitabine/bevacizumab/CPT-11/irinotecan	Response monitoring	[223]
Arend et al., 2018	Stage III-IV HGSOC	14	NGS	50 gene Ion Torrent panel	Platinum + taxane agent	Response monitoring	[188]
Lin et al., 2019	High Grade Serous and Endometriod	97	NGS	BRCA reversion mutation, TP53	PARPi (rucaparib)	Predict primary and acquired resistance	[212]
Kim et al., 2018	Stage II-IV HGSOC	102	Sanger sequencing/Digital PCR	TP53 mutation	Carboplatin + paclitaxel	Response monitoring	[189]
Oikkonen et al., 2019	HGSOC	12	NGS	ERBB2 amplification	Platinum + taxane agent ± trastuzumab	Response monitoring	[224]
Iwahashi et al., 2019	Stage I-IV HGSOC, Mucinous, Endometrioid	4	CAPP-seq	TP53, APC, BRCA1 and KRAS mutations	Carboplatin + paclitaxel	Response monitoring	[225]
Noguchi et al., 2020	Stage III-IV HGSOC	10	CAPP-seq	gene mutation profiles, blood tumor mutation burden	Carboplatin + paclitaxel ± bevacizumab	Response monitoring	[226]
Han et al., 2020	Stage III-IV EOC	10	NGS	88 genes panel (Axen Cancer Panel 1)	Standard chemotherapy	Response monitoring	[227]
Alves et al. 2020	Stage I-IV Serous, Clear Cell, Mucinous	11	qPCR	Level	Carboplatin + paclitaxel, gemcitabine, doxorubicin + bevacizumab or rucaparib (PARPi)	Response monitoring	[228]

Back to article page